Develops drugs for breast cancer and lung cancer.
Jun 2026Revenue $231M/yrExpenses $201M/yr
Reached break-even May 2022
Figures by year
When did Puma Biotechnology become profitable?
Its revenue passed its expenses in May 2022. In the 12 months to Jun 2026, revenue was $231M and expenses $201M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $228M | $191M | $37.3M |
| Dec 2024 | $230M | $200M | $31.0M |
| Dec 2023 | $236M | $203M | $32.6M |
| Dec 2022 | $228M | $204M | $23.7M |
| Dec 2021 | $253M | $252M | $1.29M |
| Dec 2020 | $225M | $256M | −$30.4M |
| Dec 2019 | $272M | $311M | −$39.0M |
| Dec 2018 | $251M | $346M | −$94.7M |
| Dec 2017 | $27.7M | $320M | −$292M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.